Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 155

1.

Pathway analysis of genome-wide data improves warfarin dose prediction.

Daneshjou R, Tatonetti NP, Karczewski KJ, Sagreiya H, Bourgeois S, Drozda K, Burmester JK, Tsunoda T, Nakamura Y, Kubo M, Tector M, Limdi NA, Cavallari LH, Perera M, Johnson JA, Klein TE, Altman RB.

BMC Genomics. 2013;14 Suppl 3:S11. doi: 10.1186/1471-2164-14-S3-S11. Epub 2013 May 28.

2.

Genetic variants associated with warfarin dose in African-American individuals: a genome-wide association study.

Perera MA, Cavallari LH, Limdi NA, Gamazon ER, Konkashbaev A, Daneshjou R, Pluzhnikov A, Crawford DC, Wang J, Liu N, Tatonetti N, Bourgeois S, Takahashi H, Bradford Y, Burkley BM, Desnick RJ, Halperin JL, Khalifa SI, Langaee TY, Lubitz SA, Nutescu EA, Oetjens M, Shahin MH, Patel SR, Sagreiya H, Tector M, Weck KE, Rieder MJ, Scott SA, Wu AH, Burmester JK, Wadelius M, Deloukas P, Wagner MJ, Mushiroda T, Kubo M, Roden DM, Cox NJ, Altman RB, Klein TE, Nakamura Y, Johnson JA.

Lancet. 2013 Aug 31;382(9894):790-6. doi: 10.1016/S0140-6736(13)60681-9. Epub 2013 Jun 5.

3.

A genome-wide association study confirms VKORC1, CYP2C9, and CYP4F2 as principal genetic determinants of warfarin dose.

Takeuchi F, McGinnis R, Bourgeois S, Barnes C, Eriksson N, Soranzo N, Whittaker P, Ranganath V, Kumanduri V, McLaren W, Holm L, Lindh J, Rane A, Wadelius M, Deloukas P.

PLoS Genet. 2009 Mar;5(3):e1000433. doi: 10.1371/journal.pgen.1000433. Epub 2009 Mar 20.

4.

New genetic variant that might improve warfarin dose prediction in African Americans.

Schelleman H, Brensinger CM, Chen J, Finkelman BS, Rieder MJ, Kimmel SE.

Br J Clin Pharmacol. 2010 Sep;70(3):393-9. doi: 10.1111/j.1365-2125.2010.03709.x.

5.

The missing association: sequencing-based discovery of novel SNPs in VKORC1 and CYP2C9 that affect warfarin dose in African Americans.

Perera MA, Gamazon E, Cavallari LH, Patel SR, Poindexter S, Kittles RA, Nicolae D, Cox NJ.

Clin Pharmacol Ther. 2011 Mar;89(3):408-15. doi: 10.1038/clpt.2010.322. Epub 2011 Jan 26.

6.

Influence of CYP2C9 and VKORC1 on warfarin response during initiation of therapy.

Limdi NA, Wiener H, Goldstein JA, Acton RT, Beasley TM.

Blood Cells Mol Dis. 2009 Jul-Aug;43(1):119-28. doi: 10.1016/j.bcmd.2009.01.019. Epub 2009 Mar 17.

7.

Predicting warfarin dosage in European-Americans and African-Americans using DNA samples linked to an electronic health record.

Ramirez AH, Shi Y, Schildcrout JS, Delaney JT, Xu H, Oetjens MT, Zuvich RL, Basford MA, Bowton E, Jiang M, Speltz P, Zink R, Cowan J, Pulley JM, Ritchie MD, Masys DR, Roden DM, Crawford DC, Denny JC.

Pharmacogenomics. 2012 Mar;13(4):407-18. doi: 10.2217/pgs.11.164. Epub 2012 Feb 13.

8.

Identification of cytochrome P450 oxidoreductase gene variants that are significantly associated with the interindividual variations in warfarin maintenance dose.

Zhang X, Li L, Ding X, Kaminsky LS.

Drug Metab Dispos. 2011 Aug;39(8):1433-9. doi: 10.1124/dmd.111.038836. Epub 2011 May 11.

9.

Novel CYP2C9 and VKORC1 gene variants associated with warfarin dosage variability in the South African black population.

Mitchell C, Gregersen N, Krause A.

Pharmacogenomics. 2011 Jul;12(7):953-63. doi: 10.2217/pgs.11.36. Epub 2011 Jun 2.

PMID:
21635147
10.

CYP2C9*8 is prevalent among African-Americans: implications for pharmacogenetic dosing.

Scott SA, Jaremko M, Lubitz SA, Kornreich R, Halperin JL, Desnick RJ.

Pharmacogenomics. 2009 Aug;10(8):1243-55. doi: 10.2217/pgs.09.71.

11.

Association of Vitamin K epoxide reductase complex 1 (VKORC1) variants with warfarin dose in a Hong Kong Chinese patient population.

Veenstra DL, You JH, Rieder MJ, Farin FM, Wilkerson HW, Blough DK, Cheng G, Rettie AE.

Pharmacogenet Genomics. 2005 Oct;15(10):687-91.

PMID:
16141794
12.

Influence of CYP2C9 and VKORC1 on warfarin dose, anticoagulation attainment and maintenance among European-Americans and African-Americans.

Limdi NA, Arnett DK, Goldstein JA, Beasley TM, McGwin G, Adler BK, Acton RT.

Pharmacogenomics. 2008 May;9(5):511-26. doi: 10.2217/14622416.9.5.511.

13.

Genome-wide association study identifies genetic determinants of warfarin responsiveness for Japanese.

Cha PC, Mushiroda T, Takahashi A, Kubo M, Minami S, Kamatani N, Nakamura Y.

Hum Mol Genet. 2010 Dec 1;19(23):4735-44. doi: 10.1093/hmg/ddq389. Epub 2010 Sep 10.

PMID:
20833655
14.

Polymorphisms in the VKORC1 gene are strongly associated with warfarin dosage requirements in patients receiving anticoagulation.

Li T, Lange LA, Li X, Susswein L, Bryant B, Malone R, Lange EM, Huang TY, Stafford DW, Evans JP.

J Med Genet. 2006 Sep;43(9):740-4. Epub 2006 Apr 12.

15.

Allelic variants in the CYP2C9 and VKORC1 loci and interindividual variability in the anticoagulant dose effect of warfarin in Italians.

Borgiani P, Ciccacci C, Forte V, Romano S, Federici G, Novelli G.

Pharmacogenomics. 2007 Nov;8(11):1545-50.

PMID:
18034619
16.

Association of VKORC1 and CYP2C9 polymorphisms with warfarin dose requirements in Japanese patients.

Mushiroda T, Ohnishi Y, Saito S, Takahashi A, Kikuchi Y, Saito S, Shimomura H, Wanibuchi Y, Suzuki T, Kamatani N, Nakamura Y.

J Hum Genet. 2006;51(3):249-53. Epub 2006 Jan 24.

PMID:
16432637
17.

Factors influencing warfarin dose requirements in African-Americans.

Momary KM, Shapiro NL, Viana MA, Nutescu EA, Helgason CM, Cavallari LH.

Pharmacogenomics. 2007 Nov;8(11):1535-44.

PMID:
18034618
18.

Influence of genetic, biological and pharmacological factors on warfarin dose in a Southern Brazilian population of European ancestry.

Botton MR, Bandinelli E, Rohde LE, Amon LC, Hutz MH.

Br J Clin Pharmacol. 2011 Sep;72(3):442-50. doi: 10.1111/j.1365-2125.2011.03942.x.

19.

Similarity in recombination rate and linkage disequilibrium at CYP2C and CYP2D cytochrome P450 gene regions among Europeans indicates signs of selection and no advantage of using tagSNPs in population isolates.

Pimenoff VN, Laval G, Comas D, Palo JU, Gut I, Cann H, Excoffier L, Sajantila A.

Pharmacogenet Genomics. 2012 Dec;22(12):846-57. doi: 10.1097/FPC.0b013e32835a3a6d.

PMID:
23089684
20.

Prediction of warfarin dose reductions in Puerto Rican patients, based on combinatorial CYP2C9 and VKORC1 genotypes.

Valentin II, Vazquez J, Rivera-Miranda G, Seip RL, Velez M, Kocherla M, Bogaard K, Cruz-Gonzalez I, Cadilla CL, Renta JY, Feliu JF, Ramos AS, Alejandro-Cowan Y, Gorowski K, RuaƱo G, Duconge J.

Ann Pharmacother. 2012 Feb;46(2):208-18. doi: 10.1345/aph.1Q190. Epub 2012 Jan 24.

Supplemental Content

Support Center